Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
52results about How to "Few effect" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
The present invention relates to pharmaceutical compositions of linagliptin, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders.
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20110046076A1Improve blood sugar controlPrevent and slow progressionBiocideMetabolism disorderAcute hyperglycaemiaIGT - Impaired glucose tolerance
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20110046087A1Prevent and slow progressionImprove blood sugar controlBiocideSenses disorderIGT - Impaired glucose toleranceAcute hyperglycaemia
The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
InactiveUS20110014284A1Good effectFew compliancePowder deliveryBiocidePharmaceutical drugMedicinal chemistry
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20140315832A1Good effectFew complianceBiocidePeptide/protein ingredientsPrediabetesInternal medicine
The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and / or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
Owner:BOEHRINGER INGELHEIM INT GMBH
Peptides that inhibit complement activation
ActiveUS20050090448A1Great bioavailabilityFew effectPeptide/protein ingredientsAntinoxious agentsPeptideImmunology
The present invention relates to compositions, including pharmaceutical compositions that inhibit complement activation, and contain amino acid sequences X1-X2-X3-W-E-X4-X5-X6 and / or Z1-C1-Z2-P-Z3-Z4-C2-Z5 as described. The invention further relates to methods of inhibiting complement activation in vivo or ex vivo by administering a pharmaceutical composition as described herein.
Owner:BAXALTA GMBH
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20140303097A1Good effectFew complianceBiocideMetabolism disorderOxidative stressPharmaceutical drug
The present invention relates to certain SGLT-2 inhibitors for treating and / or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and / or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and / or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
The present invention relates to certain SGLT-2 inhibitors for treating and / or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
ActiveUS9949998B2Good effectFew complianceOrganic active ingredientsMetabolism disorderPre diabetesKidney injury
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20160000816A1Good effectFew complianceBiocideCarbohydrate active ingredientsOxidative stressBlood vessel
The present invention relates to certain SGLT-2 inhibitors for treating and / or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and / or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and / or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20120196812A1Good effectFew complianceBiocideSenses disorderAcute hyperglycaemiaIGT - Impaired glucose tolerance
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
ActiveUS20140038911A1Good effectFew complianceBiocideMetabolism disorderAcute hyperglycaemiaIGT - Impaired glucose tolerance
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20130035298A1Reduce riskFew complianceBiocideMetabolism disorderKidney injuryMetabolic disorder
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
InactiveUS20140088027A1Prevent and slow progressionImprove blood sugar controlBiocideNervous disorderAcute hyperglycaemiaIGT - Impaired glucose tolerance
The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor and a PPARγ agonist which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Owner:BOEHRINGER INGELHEIM INT GMBH
Image processor, image processing method and image processing program
InactiveUS20060055711A1Few effectLow costImage analysisCathode-ray tube indicatorsImaging processingComputer graphics (images)
An image processing method and an image processor for drawing the movements of such linear objects as fur, hair, and grass of a turf being influenced by wind have not been proposed thus far. The present invention provides image processing method executed by an image processor for projecting and drawing linear objects viewed from view point on a two-dimensional plane when the view point, ground, and linear objects, of which one end of each linear object is fixed on the ground, are positioned in virtual three-dimensional space, comprising a drawing step of layering the cross-sections of linear objects created by cutting the plurality of linear objects at planes which are parallel with the ground for each of planes as semi-transparent layers, and a redrawing step of moving the semi-transparent layers in a predetermined direction after a predetermined time elapsed and redrawing the semi-transparent layer(s) on the two-dimensional plane.
Owner:SEGA CORP
Transdermal drug delivery devices containing O-Desmethyl Venlafaxine (ODV) or its salts
InactiveUS20070053968A1Simple and convenient and non-invasive administrationFast deliveryOrganic active ingredientsBiocideVasomotor symptomSerotonin
The present invention provides transdermal drug delivery devices (i.e., patches) comprising O-desmethylvenlafaxine (ODV), a selective serotonin and norepinephrine re-uptake inhibitor, or a pharmaceutically acceptable salt thereof, which, among other, offer the advantage of eliminating or reducing the adverse side effects associated with the oral administration of ODV. Also provided are methods of preparing and using these transdermal delivery systems for the treatment of depression, anxiety disorders, vasomotor symptoms and pain.
Owner:WYETH LLC
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20160038525A1Good effectFew complianceBiocidePeptide/protein ingredientsPrediabetesInternal medicine
Owner:BOEHRINGER INGELHEIM INT GMBH
Platinum(II) and platinum(IV) complexes and their use
InactiveUS20050026896A1Improve therapeutic indexFew effectBiocidePlatinum organic compoundsPt elementPlatinum complex
Platinum(II) complexes are provided selected from the group consisting of compounds of the general formulae I to IV and physiologically acceptable addition salts thereof, wherein the radicals R1 to R4, R1′ to R3′, X, X′, Y, a, i, k and n are defined as in the description, and mixtures of the compounds for use as prophylactic and / or therapeutic agents for the treatment of diseases, and cytostatic platinum complexes with the general formulae[PtII(NH3)n(A)n(Z)2-n] or [PtIV(NH3)n(A)n(Z)2-nX2]and[PtII(A)1(Z)2] or [PtIV(A)1(Z)2X2]wherein A, Z and n are as defined in the description.
Owner:FAUSTUS FORSCHUNGS CIE TRANSLATIONAL CANCER RES
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
InactiveUS20180104249A1Few complianceFew convenienceSenses disorderNervous disorderMetabolic disorderDosage form
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20190038654A1Good effectFew complianceOrganic active ingredientsCoatingsOxidative stressBlood vessel
The present invention relates to certain SGLT-2 inhibitors for treating and / or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and / or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and / or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
ActiveUS20160038523A1Good effectFew complianceBiocideMetabolism disorderOxidative stressBlood vessel
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
ActiveUS20160038524A1Few complianceFew convenienceBiocideMetabolism disorderPre diabetesKidney injury
The present invention relates to certain SGLT-2 inhibitors for treating and / or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
Owner:BOEHRINGER INGELHEIM INT GMBH
Antiviral phosphinate compounds
ActiveUS20080057031A1Improve oral bioavailabilityFew effectBiocideDigestive systemCombinatorial chemistryAnti virals
The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Owner:GILEAD SCI INC
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
InactiveUS20180289678A1Good effectFew complianceMetabolism disorderPharmaceutical non-active ingredientsMetabolic disorderDosage form
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20180214468A1Good effectFew complianceOrganic active ingredientsMetabolism disorderKidney injuryMetabolic disorder
Owner:BOEHRINGER INGELHEIM INT GMBH
Methods and Compositions for Treatment of Macular and Retinal Disease
InactiveUS20070259843A1Convenient treatmentImprove efficacyBiocideSenses disorderExudative age-related macular degenerationDisease cause
The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs to treat such blinding retinal disease such as age-related macular degeneration, retinoblastoma, and diabetic macular edema. For example, the present invention comprises a method for the treatment of a disorder of the eye comprising linking a therapeutic agent to a xanthophyll carotenoid to create a prodrug, and administering a therapeutically effective amount of the prodrug to an individual in need of treatment. Provided are prodrugs for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or inflammatory disorders.
Owner:UNIV OF GEORGIA RES FOUND INC
Method and device for determining an operating parameter of a shockwave source
In a method to determine an operating parameter of a shockwave source for the generation of a shockwave to disintegrate a calculus in a patient by a shockwave lithotripsy, a characteristic of the patient and / or of the calculus is determined before and / or during the shockwave lithotripsy and the operating parameter is automatically determined dependent on the characteristic. A device for determining an operating parameter of a shockwave source for the destruction of a calculus in a patient has an acquisition and control unit for determination and / or input of a characteristic of the patient and / or of the calculus, and for automatic determination of the operating parameter dependent on the characteristic.
Owner:SIEMENS AG
Novel Nucleic Acid Having Adjuvanticity and Use Thereof
ActiveUS20130178611A1Strong adjuvanticityFew effectOrganic active ingredientsSugar derivativesSide effectSingle strand dna
The disclosed nucleic acid at least containing a single-stranded DNA to be delivered to endosomes of dendritic cells and a double-stranded RNA capable of activating TLR3 can be delivered to endosomal TLR3 and has a strong adjuvanticity with few side effects, and therefore is useful as an active ingredient of immunostimulants, vaccine adjuvants, cancer therapeutic agents and the like.
Owner:INST OF ADVANCED IMMUNOTHERAPY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com